AbbVie Foe Coherus Sways PTAB To Review Humira Patent

The Patent Trial and Appeal Board of the US Patent & Trademark Office has agreed to hold a trial under its inter partes review process to consider the validity of one of AbbVie Inc.'s dosing methods patents. The challenger, Coherus BioSciences Inc., is hoping to eventually market a biosimilar of Humira in the US.

Biosimilar firm Coherus BioSciences Inc. succeeded under its inter partes review (IPR) petition in convincing the Patent Trial and Appeal Board (PTAB) of the US Patent & Trademark Office (US PTO) there was a reasonable likelihood a dosing methods patent held by AbbVie Inc. on its main moneymaker Humira (adalimumab) was invalid and won the right to challenge it in a trial.

The PTAB's decision to institute a trial on five claims of AbbVie's patent 8,889,135-B2 – the '135 patent – sent...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip